Kevin (@BiochemKev) header
Kevin (@BiochemKev) profile picture

UBC PhD Candidate in Pharmaceutical Science Building next gen LNP-RNA w/ biomimetic design Beating the market w/ commercial stage biotechs

Vancouver, BC
Joined February 2021
Photo by Kevin (@BiochemKev)Photo by Kevin (@BiochemKev)Photo by Kevin (@BiochemKev)Photo by Kevin (@BiochemKev)Photo by Kevin (@BiochemKev)Photo by Kevin (@BiochemKev)Photo by Kevin (@BiochemKev)Photo by Kevin (@BiochemKev)Photo by Kevin (@BiochemKev)Photo by Kevin (@BiochemKev)
Kevin retweeted
$PRME Danaher just put prime editing and base editing on the shelf. IDT + Aldevron, Nov 4:
 • PE Ultra prime editor mRNA, chemically modified Alt-R pegRNAs, and a pegRNA design tool
 • Six stocked ABE8e base editors, plus a kit to screen all six at once
 • 20 µg to 1 mg in stock, larger runs custom Research grade. No CGMP timeline announced. What it replaces: sourcing a plasmid, making your own mRNA, and working out guide design by trial and error. Stocked inventory is a forecast. Danaher builds those with a spreadsheet, not a press release. Same two companies manufactured the components for the world's first mRNA-based personalized CRISPR therapy. Every target proven in an animal needs a human therapeutic license to go further.
2
4
20
2,312
$ARWR #JPM26 Obesity “will include combo studies with Tirzepatide and other GLPs to see if INHBE and ALK7 can be used as maintenance therapy once GLPs are removed. Expanding to dimers targeting 2 adipose targets, 2 liver targets, and subQ CNS platform to hit central targets."
2
1
34
2,639
"Let me be clear, we are not looking to partner INHBE or ALK7 right now. We think there's too much value for us to create by ourselves. Phase 2s could be really value generating. It's important to keep these wholly owned. We have the cash to push all of these programs forward."
15
593
UBC is becoming a world leader in acedemic led drug development! "Leading an initiative known as Canada's Immuno-Engineering and Biomanufacturing Hub, which includes involvement from many other academic institutions, and aims to quicken drug development" biv.com/news/technology/bc-c…
6
391
Arrowhead Pharmaceuticals ($ARWR) is the weirdest company in the world. 🧬 In 2011, they bought a $1 billion tech portfolio for "pennies" while drinking pints in a London pub. Now, they are silencing genes to save lives. Here is the story of the ultimate Biotech Renaissance. 🧵 #BioTech #ARWR #Investing #Genomics 1/11
4
10
3
46
9,945
From Stifel: top 15 pub traded RNA therapeutics companies
8
20
115
14,070
4/ Yesterday Capstan Broke the Trend AbbVie paid $2.1B for Capstan’s in-vivo CAR-T at Phase 1. That’s 10–15x the typical single-asset price tag. Why? Because Capstan isn’t a product. It’s a platform. fiercebiotech.com/biotech/ab…
2
2
3
19
7,480
Dr. Pieter Cullis is changing the world, one tiny lipid nanoparticle at a time! cihr-irsc.gc.ca/e/54321.html…
13
30
2,859
Interesting comments on extrahepatic targeting of LNPs from a pioneer in the field.
𝐅𝐫𝐨𝐦 𝐕𝐚𝐧𝐜𝐨𝐮𝐯𝐞𝐫: Professor Pieter Cullis and Jay Kulkarni, co-founders of NanoVation Therapeutics, discusses the next generation of lipid nanoparticle delivery. Full video: biotechtv.com/post/nanovatio…
1
1
27
8,166
“First successful clinical correction of a mutation in DNA” achieved by an LNP delivered Base Editor $BEAM
12
931
$ARWR some preclinical results of ARO-ALK7 (silencing with #Tirzepatide from $LLY). Investors need patience, but the opportunities for the #RNAi play in the obesity market are great in the long term. ir.arrowheadpharma.com/stati…
4
1
35
2,709
$ARWR: I bought $ARWR because I wanted more late stage companies with multiple drugs and multiple indications that could offer a lot of potential. I bought because the valuation was way below my estimates I bought because they have 2 later stage programs in cholesterol which are very competitive spaces. I am hopeful they can compete with other therapies in this space. I bought because they have 2 early obesity programs that could be huge if they are successful. They offer the option of the upside at a much better valuation than other companies in this space that are over hyped. I bought because they seem to have a sound management team and a good balance sheet. I bought because I can buy more cheaper if the sector crashes, but I could also sell for big profits if the sector rallies. I like that I am not married to the company so I can be flexible if my strategy changes.
1
2
1
16
2,919
RIP to a gene therapy pioneer 🫡 Unfortuantly Ex-Vivo lentiviral gene insertion was a poor delivery tech to begin with. Requiring myeloablative conditioning, fertility risks, and CL2+ viral vector production. In-Vivo LNP gene editing will be the holy grail imo.
1
7
441
$ALLO Cema-cel vs. $GILD Yescarta in LBCL. Comparable CR with lower side effects and longer duration. Very impressive for an off the shelf CAR-T!
Full Ph1 ALPHA/ALPHA2 cema-cel data in @JCO_ASCO, demonstrating long-term durability of a 1x Tx in r/r #LBCL patients with our investigational allogeneic #CART and 100% CR in patients with low disease burden – the focus of our ALPHA3 trial in 1L. $ALLO @DrFredLocke Learn more about cema-cel: ir.allogene.com/news-release…
6
517
$BMY looking to free up $2B for M&A. $TGTX Briumvi and AzerCel would look very nice in their MS portfolio next to Zepovia (1st line oral). Maybe MW told them to come back with more cash. endpts.com/bristol-myers-lau…
3
1
21
2,843
$SRPT at JPM25 saying what $ARWR investors have known for years. $ARWR TRiM platform is best in class siRNA by: Tissue targeting Dosing frequency Adverse events Efficacy
2
5
51
6,227
Big opportunity for a Duchenne gene therapy that actually works!
$SRPT CEO says demand for their gene therapy is overwhelming. Haven’t even dosed 5% of eligible patients.
14
5
108
33,560
So wonderful to see Tim Harris’ book on biotech arrive from Amazon today! This is a MUST read for anyone interested in the history of biotech! Enjoy!!!
6
7
1
69
4,881
I have no doubt $IONS is pissed that they only received the smaller label (genetic FCS) with a max of 3k patients. If they don't run a ph3 for clinical FCS then they're basically admitting $ARWR is superior. #GameOver
4
3
49
4,841